Chemomab Therapeutics (CMMB) Competitors

$1.63 +0.01 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$1.65 +0.02 (+1.41%)

As of 07:15 PM Eastern

CMMB vs. LIXT, ELUT, MIRA, LITS, and ATRA

Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Lixte Biotechnology (LIXT), Elutia (ELUT), MIRA Pharmaceuticals (MIRA), Lite Strategy (LITS), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

How does Chemomab Therapeutics compare to Lixte Biotechnology?

Chemomab Therapeutics (NASDAQ:CMMB) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

: Chemomab Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 1,433.74%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Lixte Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemomab Therapeutics
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Lixte Biotechnology
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Chemomab Therapeutics' return on equity of -103.85% beat Lixte Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Chemomab Therapeutics N/A -103.85% -90.44%
Lixte Biotechnology N/A -242.85% -115.18%
: Lixte Biotechnology is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chemomab Therapeutics N/A N/A -$8.99M -$2.56 N/A
Lixte Biotechnology N/A N/A -$6.01M -$1.24 N/A
: 46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Chemomab Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
: In the previous week, Chemomab Therapeutics' average media sentiment score of 0.00 beat Lixte Biotechnology's score of -1.32 indicating that Chemomab Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Chemomab Therapeutics Neutral
Lixte Biotechnology Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-103.85%	-90.44%
Lixte Biotechnology	N/A	-242.85%	-115.18%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.56	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.24	N/A

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
Lixte Biotechnology	Negative

Summary

Chemomab Therapeutics beats Lixte Biotechnology on 9 of the 12 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Elutia?

Chemomab Therapeutics (NASDAQ:CMMB) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

: Elutia has a net margin of 282.63% compared to Chemomab Therapeutics' net margin of 0.00%. Elutia's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Chemomab Therapeutics N/A -103.85% -90.44%
Elutia 282.63% N/A -49.57%
: Chemomab Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 1,433.74%. Elutia has a consensus price target of $6.00, indicating a potential upside of 514.94%. Given Chemomab Therapeutics' higher possible upside, equities analysts plainly believe Chemomab Therapeutics is more favorable than Elutia.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemomab Therapeutics
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Elutia
0 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.50
: 46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Elutia has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chemomab Therapeutics N/A N/A -$8.99M -$2.56 N/A
Elutia $12.29M 3.40 $53.38M $0.82 1.19
: In the previous week, Elutia had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 1 mentions for Elutia and 0 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.00 equaled Elutia'saverage media sentiment score.
Company Overall Sentiment
Chemomab Therapeutics Neutral
Elutia Neutral
: Chemomab Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-103.85%	-90.44%
Elutia	282.63%	N/A	-49.57%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.56	N/A
Elutia	$12.29M	3.40	$53.38M	$0.82	1.19

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
Elutia	Neutral

Summary

Elutia beats Chemomab Therapeutics on 12 of the 13 factors compared between the two stocks.

How does Chemomab Therapeutics compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

: In the previous week, MIRA Pharmaceuticals' average media sentiment score of 0.00 equaled Chemomab Therapeutics'average media sentiment score.
Company Overall Sentiment
MIRA Pharmaceuticals Neutral
Chemomab Therapeutics Neutral
: Chemomab Therapeutics' return on equity of -103.85% beat MIRA Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
MIRA Pharmaceuticals N/A -210.90% -198.94%
Chemomab Therapeutics N/A -103.85% -90.44%
: Chemomab Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,433.74%. Given Chemomab Therapeutics' higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than MIRA Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Chemomab Therapeutics
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MIRA Pharmaceuticals N/A N/A -$10.44M -$1.53 N/A
Chemomab Therapeutics N/A N/A -$8.99M -$2.56 N/A
: 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: MIRA Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Chemomab Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-210.90%	-198.94%
Chemomab Therapeutics	N/A	-103.85%	-90.44%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.53	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.56	N/A

Summary

Chemomab Therapeutics beats MIRA Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

: In the previous week, Lite Strategy's average media sentiment score of 0.00 equaled Chemomab Therapeutics'average media sentiment score.
Company Overall Sentiment
Lite Strategy Neutral
Chemomab Therapeutics Neutral
: Lite Strategy's return on equity of -68.86% beat Chemomab Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Lite Strategy N/A -68.86% -67.48%
Chemomab Therapeutics N/A -103.85% -90.44%
: Chemomab Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,433.74%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than Lite Strategy.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lite Strategy
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Chemomab Therapeutics
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Chemomab Therapeutics has lower revenue, but higher earnings than Lite Strategy. Lite Strategy is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lite Strategy $65.30M 0.63 -$15.94M -$1.33 N/A
Chemomab Therapeutics N/A N/A -$8.99M -$2.56 N/A
: 52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are held by institutional investors. 1.6% of Lite Strategy shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Lite Strategy has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Company	Overall Sentiment
Lite Strategy	Neutral
Chemomab Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-68.86%	-67.48%
Chemomab Therapeutics	N/A	-103.85%	-90.44%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.63	-$15.94M	-$1.33	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.56	N/A

Summary

Chemomab Therapeutics beats Lite Strategy on 7 of the 12 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Atara Biotherapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

: 46.0% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Chemomab Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.
: Atara Biotherapeutics has a net margin of 27.07% compared to Chemomab Therapeutics' net margin of 0.00%. Atara Biotherapeutics' return on equity of -79.12% beat Chemomab Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Chemomab Therapeutics N/A -103.85% -90.44%
Atara Biotherapeutics 27.07% -79.12% 87.55%
: Atara Biotherapeutics has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chemomab Therapeutics N/A N/A -$8.99M -$2.56 N/A
Atara Biotherapeutics $120.77M 0.34 $32.69M $3.12 1.53
: Chemomab Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 1,433.74%. Atara Biotherapeutics has a consensus price target of $6.00, suggesting a potential upside of 26.05%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Atara Biotherapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemomab Therapeutics
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Atara Biotherapeutics
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
: In the previous week, Atara Biotherapeutics had 19 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 19 mentions for Atara Biotherapeutics and 0 mentions for Chemomab Therapeutics. Atara Biotherapeutics' average media sentiment score of 0.00 beat Chemomab Therapeutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Chemomab Therapeutics Neutral
Atara Biotherapeutics Neutral

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-103.85%	-90.44%
Atara Biotherapeutics	27.07%	-79.12%	87.55%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.56	N/A
Atara Biotherapeutics	$120.77M	0.34	$32.69M	$3.12	1.53

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
Atara Biotherapeutics	Neutral

Summary

Atara Biotherapeutics beats Chemomab Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Chemomab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMMB vs. The Competition

Export

Metric	Chemomab Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.65M	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	-0.64	38.57	29.25	27.07
Price / Sales	N/A	280.02	504.68	73.47
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	0.82	7.05	9.67	6.69
Net Income	-$8.99M	$23.62M	$3.55B	$332.64M
7 Day Performance	10.51%	3.67%	1.70%	2.01%
1 Month Performance	4.49%	7.17%	5.62%	9.19%
1 Year Performance	-69.36%	67.04%	34.42%	39.59%

Chemomab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMMB Chemomab Therapeutics	1.8348 of 5 stars	$1.63 +0.6%	$25.00 +1,433.7%	N/A	$11.65M	N/A	N/A	20	Upcoming Earnings
LIXT Lixte Biotechnology	0.3304 of 5 stars	$3.60 -5.3%	N/A	N/A	$44.15M	N/A	N/A	4	Negative News Upcoming Earnings
ELUT Elutia	2.788 of 5 stars	$1.00 -2.0%	$6.00 +500.0%	N/A	$43.64M	$12.29M	1.22	180	Gap Up
MIRA MIRA Pharmaceuticals	0.7404 of 5 stars	$1.01 -1.0%	N/A	N/A	$42.86M	N/A	N/A	2
LITS Lite Strategy	0.0663 of 5 stars	$1.14 -2.6%	N/A	N/A	$42.54M	$65.30M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMMB) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. LIXT, ELUT, MIRA, LITS, and ATRA

How does Chemomab Therapeutics compare to Lixte Biotechnology?

Summary

How does Chemomab Therapeutics compare to Elutia?

Summary

How does Chemomab Therapeutics compare to MIRA Pharmaceuticals?

Summary

How does Chemomab Therapeutics compare to Lite Strategy?

Summary

How does Chemomab Therapeutics compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. LIXT, ELUT, MIRA, LITS, and ATRA

How does Chemomab Therapeutics compare to Lixte Biotechnology?

Summary

How does Chemomab Therapeutics compare to Elutia?

Summary

How does Chemomab Therapeutics compare to MIRA Pharmaceuticals?

Summary

How does Chemomab Therapeutics compare to Lite Strategy?

Summary

How does Chemomab Therapeutics compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools